Governor vessel moxibustion combined with western medication for mild to moderate depression with kidney-yang deficiency : a randomized controlled trial
OBJECTIVE: To compare the therapeutic efficacy of governor vessel moxibustion combined with fluoxetine hydrochloride capsule, simple fluoxetine hydrochloride capsule and placebo moxibustion combined with fluoxetine hydrochloride capsule for mild to moderate depression with kidney-yang deficiency.
METHODS: A total of 126 patients with mild to moderate depression with kidney-yang deficiency were randomized into a governor vessel moxibustion group (42 cases, 2 cases dropped off), a western medication group (42 cases, 1 case dropped off) and a placebo moxibustion group (42 cases, 1 case dropped off). The western medication group was given fluoxetine hydrochloride capsule orally, 20 mg a time, once a day. On the basis of the treatment in the western medication group, governor vessel moxibustion was applied from Dazhui (GV 14) to Yaoshu (GV 2) in the governor vessel moxibustion group, once a week; placebo moxibustion was applied in the placebo moxibustion group, once a week. Treatment of 8 weeks was required in the 3 groups. Before and after treatment, the scores of Hamilton depression scale-17 (HAMD-17), Asberg's rating scale for side effects (SERS) and TCM clinical symptom were compared, and the clinical efficacy was evaluated.
RESULTS: After treatment, the scores of HAMD-17, SERS and TCM clinical symptom were decreased compared before treatment in the 3 groups (P<0.05), the decrease ranges of above scores in the governor vessel moxibustion group were larger than those in the western medication group and the placebo moxibustion group (P<0.05). The total effective rate was 92.5% (37/40) in the governor vessel moxibustion group, which was higher than 75.6% (31/41) in the western medication group and 80.5% (33/41) in the placebo moxibustion group (P<0.05).
CONCLUSION: Governor vessel moxibustion combined with fluoxetine hydrochloride capsule can improve the degree of depression and relieve the clinical symptoms in mild to moderate depression patients with kidney-yang deficiency, the efficacy is superior to simple fluoxetine hydrochloride capsule, and can reduce the fluoxetine hydrochloride capsule-induced adverse effect to a certain extent.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Zhongguo zhen jiu = Chinese acupuncture & moxibustion - 43(2023), 1 vom: 01. Jan., Seite 14-8 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Li, Xu-Hao [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.01.2023 Date Revised 13.01.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.13703/j.0255-2930.20220403-0001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351441999 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351441999 | ||
| 003 | DE-627 | ||
| 005 | 20231226051358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.13703/j.0255-2930.20220403-0001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351441999 | ||
| 035 | |a (NLM)36633233 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Li, Xu-Hao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Governor vessel moxibustion combined with western medication for mild to moderate depression with kidney-yang deficiency |b a randomized controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2023 | ||
| 500 | |a Date Revised 13.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To compare the therapeutic efficacy of governor vessel moxibustion combined with fluoxetine hydrochloride capsule, simple fluoxetine hydrochloride capsule and placebo moxibustion combined with fluoxetine hydrochloride capsule for mild to moderate depression with kidney-yang deficiency | ||
| 520 | |a METHODS: A total of 126 patients with mild to moderate depression with kidney-yang deficiency were randomized into a governor vessel moxibustion group (42 cases, 2 cases dropped off), a western medication group (42 cases, 1 case dropped off) and a placebo moxibustion group (42 cases, 1 case dropped off). The western medication group was given fluoxetine hydrochloride capsule orally, 20 mg a time, once a day. On the basis of the treatment in the western medication group, governor vessel moxibustion was applied from Dazhui (GV 14) to Yaoshu (GV 2) in the governor vessel moxibustion group, once a week; placebo moxibustion was applied in the placebo moxibustion group, once a week. Treatment of 8 weeks was required in the 3 groups. Before and after treatment, the scores of Hamilton depression scale-17 (HAMD-17), Asberg's rating scale for side effects (SERS) and TCM clinical symptom were compared, and the clinical efficacy was evaluated | ||
| 520 | |a RESULTS: After treatment, the scores of HAMD-17, SERS and TCM clinical symptom were decreased compared before treatment in the 3 groups (P<0.05), the decrease ranges of above scores in the governor vessel moxibustion group were larger than those in the western medication group and the placebo moxibustion group (P<0.05). The total effective rate was 92.5% (37/40) in the governor vessel moxibustion group, which was higher than 75.6% (31/41) in the western medication group and 80.5% (33/41) in the placebo moxibustion group (P<0.05) | ||
| 520 | |a CONCLUSION: Governor vessel moxibustion combined with fluoxetine hydrochloride capsule can improve the degree of depression and relieve the clinical symptoms in mild to moderate depression patients with kidney-yang deficiency, the efficacy is superior to simple fluoxetine hydrochloride capsule, and can reduce the fluoxetine hydrochloride capsule-induced adverse effect to a certain extent | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Asberg's rating scale for side effects (SERS) score | |
| 650 | 4 | |a Hamilton depression scale-17 (HAMD-17) score | |
| 650 | 4 | |a fluoxetine hydrochloride capsule | |
| 650 | 4 | |a governor vessel moxibustion | |
| 650 | 4 | |a kidney-yang deficiency | |
| 650 | 4 | |a mild to moderate depression | |
| 650 | 4 | |a placebo moxibustion | |
| 650 | 7 | |a Fluoxetine |2 NLM | |
| 650 | 7 | |a 01K63SUP8D |2 NLM | |
| 700 | 1 | |a Li, Jin-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Tian-Tian |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, Xi-Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Ji-Guo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhongguo zhen jiu = Chinese acupuncture & moxibustion |d 1995 |g 43(2023), 1 vom: 01. Jan., Seite 14-8 |w (DE-627)NLM085748544 |x 0255-2930 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:14-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.13703/j.0255-2930.20220403-0001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2023 |e 1 |b 01 |c 01 |h 14-8 | ||